Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1899 1
1908 1
1909 2
1911 1
1912 1
1913 1
1923 1
1924 2
1925 1
1926 1
1927 1
1928 1
1945 1
1947 1
1948 1
1950 1
1951 1
1952 1
1953 1
1955 1
1956 2
1957 2
1960 1
1961 2
1962 1
1963 4
1965 1
1966 3
1968 7
1969 3
1970 9
1971 4
1972 8
1973 8
1974 9
1975 7
1976 12
1977 18
1978 10
1979 8
1980 14
1981 21
1982 14
1983 11
1984 13
1985 19
1986 18
1987 12
1988 9
1989 16
1990 15
1991 10
1992 14
1993 13
1994 6
1995 12
1996 9
1997 7
1998 3
1999 13
2000 11
2001 10
2002 7
2003 11
2004 6
2005 10
2006 17
2007 7
2008 13
2009 15
2010 11
2011 9
2012 5
2013 11
2014 11
2015 12
2016 15
2017 13
2018 13
2019 16
2020 9
2021 12
2022 6
2023 21
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

633 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung G, Schneider E, Norris DA, Xia S, Bennett CF, Bishop KM. Finkel RS, et al. Lancet. 2016 Dec 17;388(10063):3017-3026. doi: 10.1016/S0140-6736(16)31408-8. Epub 2016 Dec 7. Lancet. 2016. PMID: 27939059 Clinical Trial.
BACKGROUND: Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy. Nusinersen is specifically designed to alter splicing of SMN2 pre-mRNA and thus increase the amount of functional survival motor neuron …
BACKGROUND: Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy …
Intensive care unit-acquired weakness: unanswered questions and targets for future research.
Piva S, Fagoni N, Latronico N. Piva S, et al. F1000Res. 2019 Apr 17;8:F1000 Faculty Rev-508. doi: 10.12688/f1000research.17376.1. eCollection 2019. F1000Res. 2019. PMID: 31069055 Free PMC article. Review.
ICU-AW can be caused by a critical illness polyneuropathy, a critical illness myopathy, or muscle disuse atrophy, alone or in combination. Its diagnosis requires both clinical assessment of muscle strength and complete electrophysiological evaluation of peripheral nerves a …
ICU-AW can be caused by a critical illness polyneuropathy, a critical illness myopathy, or muscle disuse atrophy, alone or in combina …
Peroneal muscular atrophy.
Hosking G. Hosking G. Dev Med Child Neurol. 1980 Jun;22(3):386-90. doi: 10.1111/j.1469-8749.1980.tb03722.x. Dev Med Child Neurol. 1980. PMID: 7390037 No abstract available.
Charcot-Marie-Tooth Disease.
Nagappa M, Sharma S, Taly AB. Nagappa M, et al. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32965834 Free Books & Documents.
Subsequently, Hoffman described thickened nerves in a patient of 'peroneal muscular atrophy'. The CMTs are heterogeneous in clinical, electrophysiological, genetic, and pathological features. ...
Subsequently, Hoffman described thickened nerves in a patient of 'peroneal muscular atrophy'. The CMTs are heterogeneous in cl …
Peroneal Atrophy.
Harris W. Harris W. Proc R Soc Med. 1908;1(Neurol Sect):54. Proc R Soc Med. 1908. PMID: 19973118 Free PMC article. No abstract available.
? Peroneal Atrophy.
Taylor J. Taylor J. Proc R Soc Med. 1913;6(Neurol Sect):50-1. Proc R Soc Med. 1913. PMID: 19976991 Free PMC article. No abstract available.
Clinical aspects of Emery-Dreifuss muscular dystrophy.
Madej-Pilarczyk A. Madej-Pilarczyk A. Nucleus. 2018 Jan 1;9(1):268-274. doi: 10.1080/19491034.2018.1462635. Nucleus. 2018. PMID: 29633897 Free PMC article. Review.
Emery-Dreifuss muscular dystrophy (EDMD), clinically characterized by scapulo-humero-peroneal muscle atrophy and weakness, multi-joint contractures with spine rigidity and cardiomyopathy with conduction defects, is associated with structural/functional defect of gen …
Emery-Dreifuss muscular dystrophy (EDMD), clinically characterized by scapulo-humero-peroneal muscle atrophy and weakness, mul …
Peroneal muscular atrophy.
DE SC, SAHA JC, SEN GUPTA SN. DE SC, et al. J Indian Med Assoc. 1957 Dec 1;29(11):444-7. J Indian Med Assoc. 1957. PMID: 13491870 No abstract available.
Hereditary Peroneal Atrophy.
[No authors listed] [No authors listed] Can Med Assoc J. 1926 Jul;16(7):834-5. Can Med Assoc J. 1926. PMID: 20315876 Free PMC article. No abstract available.
Peroneal muscular atrophy. Part 1. Clinical and electrophysiological study.
Bouché P, Gherardi R, Cathala HP, Lhermitte F, Castaigne P. Bouché P, et al. J Neurol Sci. 1983 Oct-Nov;61(3):389-99. doi: 10.1016/0022-510x(83)90172-7. J Neurol Sci. 1983. PMID: 6317809
144 patients with the clinical syndrome of peroneal muscular atrophy or Charcot-Marie-Tooth disease were studied. ...
144 patients with the clinical syndrome of peroneal muscular atrophy or Charcot-Marie-Tooth disease were studied. ...
633 results